Heritable demyelinating neuropathies, including Charcot-Marie-Tooth disease type 1A (CMT1A), account for a significant portion of peripheral nerve disorders leading to muscle atrophy and functional impairment. Peripheral myelin protein 22 (PMP22) is a hydrophobic integral membrane protein within Schwann cells, whose abnormal expression is associated with the majority of CMT1A cases. In most patients with demyelinating neuropathy, the PMP22 gene is duplicated, while in a smaller fraction of CMT1A and in Dejerine-Sottas Syndrome, single amino acid substitutions in PMP22 are present. Studies of nerve biopsies from neuropathic patients revealed abnormal retention of PMP22 within the Schwann cell cytosol, and the lack of correct myelin protein expression. To gain understanding into the subcellular pathogenesis of PMP22- associated neuropathies, we have characterized the posttranslational processing of PMP22 and found slowed degradation and abnormal intracellular accumulation of the protein within Schwann cells from neuropathic mice, including the point mutant Trembler J and the PMP22 overexpressor models. Since cytosolic PMP22 is only detected in nerve tissue from neuropathic and not normal mice, the abnormal intracellular accumulation of PMP22 likely contributes to the disease pathogenesis. Indeed, upon overwhelming the ubiquitin-proteasome pathway, cytosolic aggregates of PMP22 form and recruit essential Schwann cell molecules, including chaperones and myelin proteins, which alter the protein balance of the cell. Under permissive conditions, Schwann cells isolated from neonatal nerves have the ability to clear these abnormal cytosolic protein aggregates by a mechanism that is assisted by chaperones and autophagy. During the current cycle of this project, we stimulated the chaperone and autophagic responses within samples from Trembler J and PMP22 overexpressor mice, and found that the abnormal cytosolic aggregation of PMP22 can be suppressed and myelin production improved. Furthermore, we have shown that dietary stimulation of these pathways has proven beneficial to these neuropathic mice. The success of these proof-of-principle experiments sets the stage to move forward with specific pharmacologic treatment paradigms in neuropathic mice, and evaluate treatment outcome on neuromuscular function, nerve morphology and associated subcellular mechanisms. The overall aim of this project is to determine if pharmacologic enhancement of chaperones and autophagic protein degradation can slow or halt the progression of the neuropathy in young mice, and to investigate the response of samples from advanced disease stages to this approach. We will use pharmacologically characterized, known small molecules to stimulate the chaperone and autophagy pathways in young neuropathic mice and in ex vivo samples from advanced disease state mice. These studies will determine if improving the subcellular processing of PMP22 by stimulation of protein homeostatic mechanisms within Schwann cells could provide a viable approach for therapy in CMT1A and related neuropathies.

Public Health Relevance

Treatment options for patients with hereditary neuropathies are limited. We have identified protein chaperones and autophagy proteolysis as potential targets for treating Charcot-Marie- Tooth disease. We will now test the efficacy of small molecules that enhance these pathways to attenuate the progression of neurodegeneration in neuropathic mouse models.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS041012-12
Application #
8258767
Study Section
Cellular and Molecular Biology of Glia Study Section (CMBG)
Program Officer
Gwinn, Katrina
Project Start
2000-10-01
Project End
2014-05-31
Budget Start
2012-06-01
Budget End
2013-05-31
Support Year
12
Fiscal Year
2012
Total Cost
$304,225
Indirect Cost
$89,850
Name
University of Florida
Department
Neurosciences
Type
Schools of Medicine
DUNS #
969663814
City
Gainesville
State
FL
Country
United States
Zip Code
32611
Mattson, Mark P; Allison, David B; Fontana, Luigi et al. (2014) Meal frequency and timing in health and disease. Proc Natl Acad Sci U S A 111:16647-53
Nicks, Jessica Renee; Lee, Sooyeon; Kostamo, Kathryne Ann et al. (2013) Long-term analyses of innervation and neuromuscular integrity in the Trembler-J mouse model of Charcot-Marie-Tooth disease. J Neuropathol Exp Neurol 72:942-54
Rangaraju, Sunitha; Notterpek, Lucia (2011) Autophagy aids membrane expansion by neuropathic Schwann cells. Autophagy 7:238-9
Dugas, Jason C; Notterpek, Lucia (2011) MicroRNAs in oligodendrocyte and Schwann cell differentiation. Dev Neurosci 33:14-20
Verrier, Jonathan D; Semple-Rowland, Susan; Madorsky, Irina et al. (2010) Reduction of Dicer impairs Schwann cell differentiation and myelination. J Neurosci Res 88:2558-68
Opalach, Katherine; Rangaraju, Sunitha; Madorsky, Irina et al. (2010) Lifelong calorie restriction alleviates age-related oxidative damage in peripheral nerves. Rejuvenation Res 13:65-74
Rangaraju, Sunitha; Hankins, David; Madorsky, Irina et al. (2009) Molecular architecture of myelinated peripheral nerves is supported by calorie restriction with aging. Aging Cell 8:178-91
Verrier, Jonathan D; Lau, Pierre; Hudson, Lynn et al. (2009) Peripheral myelin protein 22 is regulated post-transcriptionally by miRNA-29a. Glia 57:1265-79
Madorsky, Irina; Opalach, Katherine; Waber, Amanda et al. (2009) Intermittent fasting alleviates the neuropathic phenotype in a mouse model of Charcot-Marie-Tooth disease. Neurobiol Dis 34:146-54
Madorsky, Irina; Opalach, Katherine; Waber, Amanda et al. (2009) Intermittent fasting alleviates the neuropathic phenotype in a mouse model of Charcot-Marie-Tooth disease. Neurobiol Dis :

Showing the most recent 10 out of 14 publications